Dose decrease of biologics in psoriasis patients with low disease activity.
- Conditions
- psoriasis, biologics, tnf-alfa remmers, etanercept, adalimumab, ustekinumab, dosis reductie, dose reduction, dose decrease
- Registration Number
- NL-OMON24722
- Lead Sponsor
- Radboudumc, Nijmegen, The Netherlands
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
(1) Treatment of at least 6 months with one biologic
(2) During the last 6 months, subsequent low disease activity scores (PASI (psoriasis area and severity index) <5) until the moment of inclusion. At least 2 PASI scores should be available.
Exclusion Criteria
• Psoriasis itself is not the main reason for biologic prescription (e.g. when a patient has RA and psoriasis, and RA is the main reason for the biologic).
• Concomitant use of immunosupressants other than methotrexate or acitretin for psoriasis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Psoriasis Area and Severity Index (PASI) at 12 months
- Secondary Outcome Measures
Name Time Method Dermatology Life Quality Index (DLQI) at 12 months <br /><br>PASI scores at each time point <br /><br>Time until flare <br /><br>Trough level antidrug antibodies and serum drug levels at each time point <br /><br>hsCRP at each time point <br /><br>SAEs